PMID- 11279651
OWN - NLM
STAT- MEDLINE
DCOM- 20010426
LR  - 20061115
IS  - 0361-8609 (Print)
IS  - 0361-8609 (Linking)
VI  - 67
IP  - 1
DP  - 2001 May
TI  - Home treatment of deep venous thrombosis with low molecular weight heparin: 
      Long-term incidence of recurrent venous thromboembolism.
PG  - 10-4
AB  - Outpatient treatment of deep venous thrombosis (DVT) with low molecular weight 
      heparin (LMWH) seems as safe and effective as inpatient treatment with 
      unfractionated heparin (UFH). However, most of the randomized trials comparing a 
      LMWH with UFH described clinical outcomes within 3-6 months. The long-term 
      incidence of recurrent VTE after treatment of DVT with LMWH remains to be 
      established. The primary objective of this retrospective study was to document 
      the long-term incidence of recurrent venous thromboembolism (VTE) in patients 
      with DVT treated with a LMWH, nadroparin in an outpatient basis. The patients 
      were evaluated 46 months after inclusion in two cohorts comparing home treatment 
      with nadroparin (n = 130) with in-hospital treatment with intravenous UFH (n = 
      149). More than 60% of the patients in the nadroparin group could be treated at 
      home, either entirely or after a short stay in hospital. The age-adjusted 
      thrombosis-free survival was not statistically significant between nadroparin and 
      UFH-treated patients (P = 0.084). There was a nonsignificant trend favoring 
      nadroparin as compared with UFH. The hazard ratio (HR) for recurrent VTE in the 
      nadroparin group with respect to the UFH group was 0.44 (95% confidence interval, 
      0.17-1.12). No significant differences were observed in overall mortality or 
      major hemorrhage between the two treatment groups. Our study suggests that home 
      treatment of DVT with LMWH is at least as effective and safe as in-hospital UFH 
      after a long-term follow-up period.
CI  - Copyright 2001 Wiley-Liss, Inc.
FAU - Grau, E
AU  - Grau E
AD  - Department of Hematology, Hospital Lluis Alcanyis, Xativa, Spain. grau_enr@gva.es
FAU - Tenias, J M
AU  - Tenias JM
FAU - Real, E
AU  - Real E
FAU - Medrano, J
AU  - Medrano J
FAU - Ferrer, R
AU  - Ferrer R
FAU - Pastor, E
AU  - Pastor E
FAU - Selfa, S
AU  - Selfa S
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Am J Hematol
JT  - American journal of hematology
JID - 7610369
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 0 (Nadroparin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Ambulatory Care/*standards
MH  - Cohort Studies
MH  - Disease-Free Survival
MH  - Female
MH  - Follow-Up Studies
MH  - Hemorrhage/chemically induced
MH  - Heparin, Low-Molecular-Weight/*administration & dosage/adverse effects/standards
MH  - Hospitalization
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Nadroparin/administration & dosage/adverse effects/standards
MH  - Recurrence
MH  - Retrospective Studies
MH  - Survival Rate
MH  - Thromboembolism/epidemiology
MH  - Venous Thrombosis/complications/*drug therapy
EDAT- 2001/04/03 10:00
MHDA- 2001/05/01 10:01
CRDT- 2001/04/03 10:00
PHST- 2001/04/03 10:00 [pubmed]
PHST- 2001/05/01 10:01 [medline]
PHST- 2001/04/03 10:00 [entrez]
AID - 10.1002/ajh.1069 [doi]
PST - ppublish
SO  - Am J Hematol. 2001 May;67(1):10-4. doi: 10.1002/ajh.1069.